| Autor: |
Manfred Kraus, Joseph Tumang, Xianxian Zheng, Li-Chin Yao, Martin Wythes, Benoit J. Van den Eynde, Konstantinos Tsaparikos, Vince R. Torti, Nicole Streiner, Chad Ray, Virginie Rabolli, Romain Pirson, Nichol Miller, Reece Marillier, Karen Maegley, Wenlin Li, Marie-Claire Letellier, Jie Guo, Valeria R. Fantin, Christopher P. Dillon, Sofie Denies, Deepak Dalvie, Stefano Crosignani, Sandra Cauwenberghs, Danying Cai, Derek Bartlett, Gregory Driessens, Bruno Gomes |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1535-7163.22505137 |
| Popis: |
Table S1 shows the plasma protein binding and blood to plasma ratio in mouse, rat, dog and human. Table S3 shows the plasma concentrations following a single oral dose of PF-06840003. Figure S1 shows that PF-06840003 does not impact cell viability. Figure S2 shows that PF-06840003 rescues T-cell proliferation in a co-culture assay. Figure S3 shows tumor growth inhibition of CT26 tumors at different dose levels. Figure S4 shows that IDO1 inhibitor mediated tumor growth inhibition depends on CD8+ T cells. Figure S5 shows a combination benefit with anti-PD-L1 treatment in CT26 tumors. Figure S6 shows IDO1i mediated tumor growth inhibition of MDA-MB-231 breast tumors in humanized mice. Figure S7 shows that PF-06840003 improves the TGI of avelumab in a humanized mouse breast tumor model. Figure S8 shows the fractions of CT26 tumor immune infiltrating cells. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
